WALTHAM, Mass.--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan family of products, announces its partnership with Gastrologix to provide independent GI practices in its group purchasing organization (GPO) with the enhanced services of FibroScan, a non-invasive device that helps to assess liver health. FibroScan is used by GI physicians to identify and address nonalcoholic fatty liver disease (NAFLD) and its more severe form nonalcoholic steatohepatitis (NASH), which have been recognized as leading causes of liver disease and key contributors to increased cardiovascular disease (CVD) mortality among people living with Type 2 diabetes.
"Given the alarming rise in liver disease, FibroScan will help independent GI practices to improve patient outcomes and reduce the costs associated with managing chronic liver conditions," says Stephen Somers, principal of Gastrologix. "This innovative technology should be an integral part of a chronic care management program in any independent GI practice. In addition to providing a valuable service to patients, FibroScan can help sustain the practice financially as well."
NAFLD has become the most common chronic liver disease in the world and affects between 25% to 30% of adults in the United States. About 20% of patients with NAFLD will progress to NASH, with about 25% of these individuals likely to develop liver fibrosis. Because NAFLD and NASH are tightly intertwined with obesity, diabetes and lifestyle, patients benefit from coordinated engagement to support changes in lifestyle that affect liver disease progression and result in better outcomes.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Jon Gingrich, CEO, Echosens North America, says "We're excited to be able to bring FibroScan to the Gastrologix customer base. GI practices are at the forefront of the fight against the liver disease epidemic and can use our technology as part of their efforts to improve outcomes, save lives and, in these challenging times, initiate income repair for their practices."
Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans. For more information, please visit http://www.echosens.us.
Gastrologix is the only Group Purchasing Organization (GPO) in the U.S. working strictly on behalf of independent gastroenterologists. Gastrologix works with independent GI practices in a business development capacity to lower costs, operate more efficiently and expand services, so that GI physicians can remain independent and continue to provide a valuable alternative to the more expensive care provided in hospitals.